Oncology · Colorectal CancerTrial Updateclinicalmid-term

Surufatinib plus FOLFOX/FOLFIRI shows potential in mCRC second-line therapy

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/10/2026, 6:32:10 PM

Assessment confidence: 59% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of surufatinib in combination with established chemotherapy regimens could significantly alter treatment paradigms in metastatic colorectal cancer. If successful, it may provide a competitive edge against existing therapies, necessitating close observation of trial outcomes and regulatory responses. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 7 ranked evidence items (2 high-relevance).

Strategic Assessment

The strongest clinical anchor is Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In colorectal cancer, 0 regulatory and 1 competitive items passed relevance filtering for surufatinib. Success in this trial could enhance surufatinib's market position, potentially increasing market share in the second-line treatment landscape for mCRC, which is a lucrative segment.

Competitive Pressure

The most relevant competitive pressure comes from City of Hope Initiates Liquid Biopsy Study for Early Colorectal Cancer Detection (Humanexa Signals) — sub-indication match (colorectal cancer). If successful, surufatinib could position itself as a key player in second-line mCRC therapy, challenging existing triplet regimens.

Regulatory Outlook

Regulatory risk is concentrated around The trial results will likely influence future regulatory decisions regarding the approval and labeling of surufatinib, impacting its commercialization strategy..

Key Risks

Elevated medium regulatory exposure for surufatinib could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

Success in this trial could enhance surufatinib's market position, potentially increasing market share in the second-line treatment landscape for mCRC, which is a lucrative segment.
The potential of surufatinib in enhancing treatment options for mCRC, impacting future development strategies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for efficacy and safety outcomes, as well as subsequent regulatory decisions.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Traditional Chinese Medicine Patch for Cancer-Related Fatigue During Radiotherapy
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

City of Hope Initiates Liquid Biopsy Study for Early Colorectal Cancer Detection
Humanexa Signalsmedium relevance
Sub-indication match (colorectal cancer)
Fluoxetine Janus dendrimer shows potent anticancer activity against MCF-7 cells
Humanexa Signalslow relevance
Broad oncology match without sub-indication specificity

Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Entity match (surufatinib)
FDA document
View source
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Patient population match (metastatic)
FDA document
View source
ADAR1-circRAB5A-BIP axis governs radiotherapy resistance in colorectal cancer through coordinating protective autophagy and apoptosis.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Comparison FT-IR spectral fingerprints of kidney Cancer in urine and serum: Clinical correlations and diagnostic potential.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

surufatinib
FOLFOX
FOLFIRI
FOLFOXIRI
metastatic colorectal cancer

Commercial impact

medium

Success in this trial could enhance surufatinib's market position, potentially increasing market share in the second-line treatment landscape for mCRC, which is a lucrative segment.

Regulatory impact

medium

The trial results will likely influence future regulatory decisions regarding the approval and labeling of surufatinib, impacting its commercialization strategy.

What to watch

Monitor trial results for efficacy and safety outcomes, as well as subsequent regulatory decisions.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.